The combination of amiodarone and beta-blockers may represent an alternative treatment in patients at risk of sudden death in whom a beneficial effect of the implantable defibrilator has not been clearly demonstrated;L'associazione amiodarone-betabloccanti può rappresentare un trattamento alternativo nei pazienti a rischio di morte improvvisa nei quali non è chiaramente dimostrato un beneficio del defibrillatore impiantabile

Italian Heart Journal Supplement

Volumn 3, Issue 3, 2002, Pages 337-343

  Alboni, Paolo ^a  

^a Ospedale Civile   (Italy)

Author keywords

Arrhythmias, ventricular; Beta blockers; Implantable cardioverter defibrillator; Sudden cardiac death

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

DEFIBRILLATOR; ELECTROPHYSIOLOGY; HEART EJECTION FRACTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; REVIEW; SUDDEN DEATH;

ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DRUG THERAPY, COMBINATION; HEMODYNAMIC PROCESSES; HUMANS; MYOCARDIAL ISCHEMIA; SYNCOPE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 0036253611     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial
2. Sudden cardiac death: Future approaches based on identification and control of transient risk factors
3. Determinants of predicted efficacy of antiarrhythmic drugs in the electrophysiologic study versus electrocardiographic monitoring trial
4. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study)
5. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
6. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
7. Randomised trial of low-dose amiodarone in severe congestive heart failure
8. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure
9. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trial
10. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial)
11. Efficacy and safety of low doses of beta-blockers agents combined with amiodarone in refractory ventricular tachycardia
12. A prospective study of the efficacy and safety of adjuvant metoprolol and xameterolol in combination with amiodarone for resistant ventricular tachycardia associated with impaired left ventricular function
13. Amiodarone interaction with β-blockers. Analysis of the merged EMIAT and CAMIAT databases
14. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
15. Canadian implantable defibrillator study (CIDS). A randomised trial of the implantable cardioverter defibrillator against amiodarone
16. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH)
17. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials
18. Significance of the clinical presentation in ventricular tachycardia/fibrillation
19. Stable ventricular tachycardia is not a benign rhythm. Insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) registry
20. Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease
21. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia
22. The 1988 NASPE prospective catheter ablation registry
23. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy
24. Long-term prognosis of patients undergoing electrophysiologic studies for syncope of unknown origin
25. Long-term outcome of patients with syncope associated with coronary heart disease and a nondiagnostic electrophysiologic evaluation
26. Programmed ventricular stimulation for arrhythmia risk prevention in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia
27. High incidence of appropriate cardioverter-defibrillator therapy in patients with syncope of unknown origin and inducible ventricular arrhythmias
28. Comparison of event rates and survival in patients with unexplained syncope without documented ventricular tachy-arrhythmias versus patients with documented sustained ventricular tachyarrhythmias both treated with implantable cardioverter-defibrillators
29. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator
30. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
31. A randomized study of the prevention of sudden death in patients with coronary artery disease
32. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery
33. Multicenter randomized trial comparing amiodarone to implantable defibrillator in patients with nonischemic cardiomyopathy and asymptomatic nonsus-tained ventricular tachycardia: AMIOVIRT trial
34. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction
35. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy
36. Impact of amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure
37. Amiodarone and carvedilol in congestive heart failure: A possible association?